Neuropathic pain drug under scrutiny

QUESTIONS about the use of adjuvant analgesic pregabalin have been raised in a report of the latest meeting of the Drug Utilisation Sub-Committee (DUSC).

DUSC, which reports to the Pharmaceutical Benefits Advisory Committee (PBAC), says PBS data shows that use of pregabalin is higher than expected and continues to rise.

The neuropathic pain drug was dispensed to more than 430,000 people